PropThink: Big Catalysts Approaching For Trius Therapeutics

[ACN Newswire] – By Jason Napodano, CFAFundamentals at Trius Therapeutics (NASDAQ:TSRX) remain solid. I see the development of tedizolid, current in its second phase 3 trial, as low risk. Data from the first phase 3 trial … more

View todays social media effects on TSRX

View the latest stocks trending across Twitter. Click to view dashboard